Optimising a Regional Faecal Calprotectin Pathway in NENC
09/10/2018 1:00 pm @ This event has now passed
Event Details
- Sarah Black
- [email protected]
- This event has now passed,
The new Faecal Calprotectin Pathway was introduced by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust. Rolled out Nationally, this programme has the potential of ultimately affecting 322,000 patients a year and can save £15M of NHS costs over two years.
Yorkshire & Humber AHSN has successfully supported the rollout of the new pathway across seven Clinical Commissioning Groups (CCGs).
Event Aims
The aims of the event are to increase the awareness and visibility of the national collaborative project. To find out more about the project in the NENC go to our Faecal Calprotectin page.
Presentations
The Faecal Calprotectin Care Pathway – Dr James Turvill
Introducing Faecal Calprotectin – The Northumberland Experience – Dr David Shovlin
Faecal Calprotectin- The South Tees Experience – Dr Darren Craig
Small Steps – Dr George Campbell
Faecal Calprotectin implementation in County Durham for IBS, IBD and beyond – Dr Anjan Dhar
Evaluation of the clinical and cost effectiveness of the York Faecal Calprotectin Care Pathway
Agenda
| 12:30-13:00 | Registration and Refreshments | |
|
13:00-13:10
|
Welcome |
Professor Julia Newton Medical Director AHSN NENC |
| 13:10-13:40 | The Faecal Calprotectin Care Pathway |
Dr James Turvill Consultant Gastroenterologist York Teaching Hospital NHS Foundation Trust |
| 13:40-13:50 | How Pacific are supporting the national spread and adoption of Faecal Calprotectin Testing |
Emma Givens Senior Innovation and Delivery Partner Pacific Team NHS Business Services Authority |
| 13:50-14:00 | Utilisation of the Faecal Calprotectin Pathway to promote implementation by the AHSN |
Victoria Vaines Programme Manager Yorkshire and Humber Academic Health Science Network |
| 14:00-14:15 | The Pit Falls of the Faecal Calprotectin Pathway |
Dr Mark Welfare Clinical Academic Northumbria Healthcare NHS Foundation Trust and Newcastle University |
| 14:15-15:15 |
Examples of Regional Implementation of the Faecal Calprotectin Pathway
Introducing Faecal Calprotectin – The Northumberland Experience Dr David Shovlin, Clinical Director of Primary Care, NHS Northumberland CCG
Faecal Calprotectin- The South Tees Experience Dr Darren Craig, Consultant, South Tees Hospitals NHS Foundation Trust
Small Steps Dr George Campbell, Planned Care and Mental Health Lead, NHS Hambleton, Richmondshire and Whitby CCG
Faecal Calprotectin implementation in County Durham for IBS, IBD and beyond Dr Anjan Dhar. Reader in Medicine (Durham University), Consultant Gastroenterologist, Clinical Lead for Gastroenterology and UGI Cancers County Durham and Darlington NHS Foundation Trust |
|
| 15:15-15:30 | Refreshment Break | |
| 15:30-16:00 | The Pilot Lower Gi Pathway |
Dr Mark Welfare Clinical Academic Northumbria Healthcare NHS Foundation Trust and Newcastle University |
| 16:00- 16:45 | Final Comments and Discussion |
Professor Julia Newton Medical Director AHSN NENC |
| 16:45 | Close | |
Why Attend?
Calprotectin testing benefits
For the GP:
- Assists diagnosis
- Clear process
For the trust:
- Alleviates waiting lists
- Increased pathology opportunities
For the CCG:
- Financial savings
For the patient:
- Accelerates diagnosis
- Only referred if required
What is Faecal Calprotectin?
Faecal Calprotectin is an innovative diagnostic test that supports GPs in discriminating between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Early identification of patients with IBD is enabling quicker referral to the expert secondary care needed to diagnose and manage their condition effectively.
It also means that patients with IBS are not unnecessarily referred to secondary care and do not have to undergo invasive investigations (such as colonoscopies) resulting in an improved patient experience, cost savings and better use of NHS clinical resources.As distinguishing between IBS and IBD is difficult, as many as 19 out of 20 patients are unnecessarily referred to secondary care, which often includes an invasive colonoscopy.